High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area

BACKGROUND: This study was to evaluate the effect of excision repair cross-complementation group 1(ERCC1) expression on response to cisplatin-based induction chemotherapy (IC) followed by concurrent chemoradiation (CCRT) in locally advanced unresectable head and neck squamous cell carcinoma (HNSCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Tai-Jan, Chen, Chang-Han, Chien, Chih-Yen, Li, Shau-Hsuan, Tsai, Hsin-Ting, Chen, Yi-Ju
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072326/
https://www.ncbi.nlm.nih.gov/pubmed/21426588
http://dx.doi.org/10.1186/1479-5876-9-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072326/
https://www.ncbi.nlm.nih.gov/pubmed/21426588
http://dx.doi.org/10.1186/1479-5876-9-31

Ejemplares similares